Schering-Plough received clarification regarding the expiration date for its rights to market golimumab worldwide, excluding the U.S., Japan and certain other Asian markets. In August 2005, Schering-Plough and Centocor stated that they were working together to move forward with their collaboration on golimumab and were taking steps to resolve the difference of opinion as to the expiration date. Schering-Plough’s rights to market golimumab will extend to 15 years after the first commer...